Awareness of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) is low among Americans who have risks associated with the diseases, according to a survey presented at the NASH Summit in Boston. Many clinical trials are currently underway regarding pharmacologic interventions in an area where diet and lifestyle are failing to curb rising incidence
A retrospective study in the journal Liver International found use of direct-acting antivirals may be associated with the reduced number of patients on a waiting list for a liver transplant for decompensated hepatitis C virus cirrhosis. Researchers found an increase in HCV patients whose indication for liver transplant was hepatocellular carcinoma during the study period,
Cross-Epidemic of Hepatitis C with Diabetes, Obesity, and Kidney Disease
A cross-sectional and prospective analyses of 13,726 participants in the third National Health and Nutrition Examination Survey found that individuals with chronic hepatitis C have a high burden of major cardiometabolic comorbidities. Diabetes and chronic kidney disease, in particular, are associated with substantial excess mortality in persons with chronic hepatitis C. See the article
Finnish researchers found that individuals with diabetes or a high waist circumference who consumed higher average amounts of alcohol were at an increased risk of developing liver disease. The findings in the journal Hepatology, based on an analysis of the Finnish Health 2000 study data involving 6,732 individuals without liver disease, revealed that the
NAFLD Linked to Higher Incidence Rates of Cancer Significantly associated with HCC, colon cancer in men, and breast cancer in women Nonalcoholic fatty liver disease (NAFLD) was tied to an increased risk of hepatocellular carcinoma (HCC), colorectal cancer in men, and breast cancer in women, South Korean researchers found. Adjusted results from an observational meta-analysis
